Akèy › Liposarkom
Etid klinik pou Liposarkom ap rekrite nan Etazini
17 etid pou Liposarkom ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX10 etid
- Boston, MA7 etid
- Queens, NY5 etid
- New York City, NY5 etid
- St. Louis, MO5 etid
- Chicago, IL5 etid
- Edison, NJ4 etid
- Atlanta, GA4 etid
- Seattle, WA3 etid
- New Rochelle, NY3 etid
- Greenburgh, NY3 etid
- Gainesville, FL3 etid
- Miami, FL3 etid
- Pittsburgh, PA3 etid
- Richmond, VA3 etid
- San Diego, CA3 etid
- Rochester, MN3 etid
- Louisville, KY3 etid
- Aurora, CO3 etid
- Phoenix, AZ3 etid
- Tampa, FL3 etid
- Columbus, OH3 etid
- Nashville, TN3 etid
Pa eta
- Arizona3 etid
- Colorado3 etid
- Connecticut3 etid
- Florid4 etid
- Georgia4 etid
- Illinois5 etid
- Kalifòni6 etid
- Kentucky3 etid
- Massachusetts7 etid
- Michigan4 etid
- Minnesota3 etid
- Missouri5 etid
- New Jersey5 etid
- New York6 etid
- Ohio6 etid
- Pennsylvania4 etid
- Tennessee4 etid
- Texas11 etid
- Virginia5 etid
- Washington3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06422806Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06498648A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06881992A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06025747A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06843967Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT04031677Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06578624Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT05711615Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Sep 3, 2026 · NCT06541262STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06975293Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Aug 6, 2026 · NCT04715191NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06239272A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT07089992Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT07377747A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT06789172Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Ap rekriteFaz 1
Laj 1 a 26 · Tout sèks · Mizajou Feb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Nov 3, 2025 · NCT06198296Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.